Form 4 for OFIX Orthofix Medical Inc.

Accepted 2022-02-03 00:00:00 ET · period of report 2022-02-01 · accession 0001209191-22-006829 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2022-02-03	2022-02-01	OFIX	DOUG RICE	CFO	A - Grant	$0.00	+22.1K	95.7K	+30%	$0
D	2022-02-03	2022-02-01	OFIX	DOUG RICE	CFO	A - Grant	$0.00	+22.1K	22.1K	New	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2022-02-01	A	A	22,131	$0.00	95,674	D	—	—	(F1) Represents time-based vesting restricted stock units that vest in 25% increments on the first, second, third and fourth anniversaries of the grant date, February 1, 2022.
2	Derivative	Performance Share Units	2022-02-01	A	A	22,131	$0.00	22,131	D	$0.00 · — to —	22,131 Common Stock	(F2) Represents performance-based vesting restricted stock units ("PSUs") that will settle as common stock on a one-for-one basis. Under the terms of the grant, the PSUs may vest based upon achieved product revenues for the 2023 fiscal year (the "Product Revenue Vesting Percentage"), as modified by a total shareholder return ("TSR") modifier (the "TSR Modifier"). The amount in the table above represents the target number of PSUs granted. The performance period of the grant is 2/1/22-1/31/25. The Product Revenue Vesting Percentage can be achieved within a range of 50% to 200% of target, based upon the level of recognized revenues. If the Product Revenue Vesting Percentage is achieved at or above the threshold level, it shall be multiplied by the TSR Modifier (ranging from 0.75 to 1.25), which shall be determined based on the Company's relative TSR during the performance period as compared to a specified peer group.